- Regeneron immunotherapy combo comes up short in melanoma trial<p>A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out bi…BioPharma Dive · 2mo ago↗ source
- Unlocking more value from mature drug products through strategic outsourcing<p>See how strategic outsourcing can maximize value and reduce costs for mature drug portfolios.</p>BioPharma Dive · 2mo ago↗ source
- <![CDATA[Dr Meeks on a Real-World Study of BCG Retreatment After BCG Failure in NMIBC]]><![CDATA[Joshua J. Meeks, MD, PhD, discusses data from a real-world study of BCG retreatment after BCG failure in NMIBC.]]>onclive